CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

CHICAGO, IL—A novel CRISPR/Cas-9-based gene-editing technique seems to safely diminish the production of a protein linked to worsening outcomes in patients with transthyretin (ATTR) amyloidosis ...

When Victoria Gray was still a baby, she started howling so inconsolably during a bath that she was rushed to the emergency room. The diagnosis was sickle-cell disease, a genetic condition that causes ...

CRISPR is in the process of a BLA for a potential breakthrough drug. The company isn't profitable and is losing its chief operating officer. CRISPR has more than $1.9 billion in cash. It opened ...

Researchers have made an important step forward toward a long-desired goal: using the gene-editing technology CRISPR to treat cancer. In a study published in Nature, scientists recruited 16 people who ...